Scancell Holdings Share News (SCLP)
SCLP Share
SCLP Share
SCLP Share
SCLP Share
SCLP
SCLP Share
SCLP Level 2
SCLP Live
SCLP Broker
SCLP Directors
SCLP Financial
SCLP
SCLP Short
SCLP
Last checked at -
Fri, 19th Feb 2021 20:13
Scancell Holdings PLC - developer of novel immunotherapies for the treatment of cancer and infectious disease - Close associate of Non-Executive Director Martin Diggle sells 400,000 shares at an aggregate price of 27.25 pence per share, worth GBP109,000.
Current stock price: 24.50p; down 115 on Friday
Year-to-date change: up 75%
By Anna Farley; annafarley@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, made an annual loss of £2.22m in the year to 30 April compared to £1.9m last year. The company development spending increased due to additional costs in pre-clinical studies for a new platform technology, while adm
Read moreAIM-listed Pharmaceuticals group Scancell Holdings announced a patent for its DNA ImmunoBody technology has been approved in the US. The patent has been granted by the United States Patent and Trademark Office (USPTO) and covers Scancell's DNA ImmunoBody platform technology. This patent is expect
Read moreLONDON (Alliance News) - Scancell Holdings PLC said Friday its DNA Immunobody technology platform had been granted a patent by the US Patent and Trademark Office. Scancell said the patent was key for the protection of its pipeline of vaccines utilising the technology. It has already been gr
Read more
Last checked at